J.P. Morgan is a global leader in financial services, offering solutions to the world's most important corporations, governments and institutions in more than 100 countries.

<p>J.P. Morgan is a global leader in financial services, offering solutions to the world's most important corporations, governments and institutions in more than 100 countries.</p>

JPMorgan

JPMorgan Chase

INNOVENT BIO

JPMorgan Transfers Cash from Fed to Treasuries in Anticipation of Rate Cuts

Since 2023, JPMorgan Chase has withdrawn nearly $350 billion in cash from its Federal Reserve account and invested most of it in U.S. government bonds to counter the threat of Federal Reserve interest rate cuts. The bank's balance at the Federal Reserve has plummeted from $409 billion at the end of 2023 to $63 billion, while its holdings of U.S. Treasury bonds have increased from $231 billion to $450 billion. This move aims to lock in higher yields in advance and protect profits from the erosion caused by interest rate cuts

JP Morgan "escapes" the Federal Reserve, launching a $350 billion attack on U.S. Treasuries!

Since 2023, JPMorgan Chase has withdrawn $350 billion in cash from the Federal Reserve account and invested it in U.S. Treasury bonds to cope with the long-term decline in interest rates. This move aims to hedge against the impact of future interest rate declines on net interest income and ensure a high yield even when the Federal Reserve cuts interest rates

$350 billion major shift! JP Morgan withdraws from Federal Reserve accounts and turns to aggressively buy U.S. Treasuries, betting real money on the continuation of interest rate cuts

JPMorgan Chase has shifted $350 billion from the Federal Reserve into U.S. Treasuries to secure higher yields amid falling interest rates. The bank's cash balance at the Fed dropped from $409 billion to $63 billion, while its Treasury holdings increased from $231 billion to $450 billion. This move aims to protect profits as the Federal Reserve cuts rates, making large cash balances less attractive. Analysts have a "Moderate Buy" rating on JPM stock, with a price target suggesting a 6.53% upside potential.

JPMorgan (JPM) Pulls $350 Billion from the Fed. Here's Why It's Buying Treasuries

JPMorgan Chase is transferring $350 billion in reserves from its Federal Reserve account to invest in U.S. Treasury bonds, aiming to lock in yields before interest rate cuts. The scale of this move is large enough to offset changes in the rest of the banks across the U.S., leading to a significant tightening of system liquidity. Some market analysts compare this move to the triggers of the 2019 repo crisis, believing it could once again become a catalyst for instability in the financial system and force the Federal Reserve to adopt more accommodative policies

The mystery of "liquidity tightening" in the U.S. market revealed? JP Morgan withdrew nearly $350 billion from the Federal Reserve account and invested it in U.S. Treasuries

JPMorgan's Voting Rights in Alphawave IP Group PLC Exceed 5%

JPMorgan Chase & Co. has acquired or disposed of voting rights in Alphawave IP Group PLC, crossing the 5% threshold. The notification was made on 16 December 2025, with the threshold crossed on 12 December 2025. JPMorgan's total voting rights in Alphawave now stand at 5.386887%.

REG - Alphawave IP Group JPMorgan Chase & Co - Holding(s) in Company

JPMorgan Launches JPMD Token on Coinbase

JPMorgan introduces JPMD token on Coinbase's Base, revolutionizing institutional payments. Read more for updates. source:

JPMorgan Launches JPMD Token on Coinbase's Base

JPMorgan issued $50 million Galaxy bonds on Solana, purchased by Coinbase and Franklin Templeton, paid in USDC. Coinbase launched x402 V2, an AI stablecoin payment protocol. SEC approved DTCC's plan to tokenize securities. FSOC removed crypto risk warning, focusing on economic growth. US Senate progresses on crypto regulation bill. CFTC retracts 2020 guidance, accelerating crypto-friendly regulation.

JPMorgan issues Galaxy bonds on Solana; Coinbase launches x402 V2.

Coinbase Global plans to launch prediction markets and tokenized stocks next week, which are two of the hottest products in the financial market. The company will unveil these products at an event on December 17, aiming to become a "universal application" that provides traders with access to a wide range of assets and markets

Keep up with the new trend! Coinbase's tokenized stock and prediction market features may launch next week

Coinbase will announce the launch of two new businesses, "prediction markets" and "tokenized stocks," at a press conference on December 17, aiming to expand its product portfolio and become a "one-stop trading platform." The tokenized stocks are developed independently by Coinbase, demonstrating its control over product design and market strategy. This move is part of Coinbase's goal to become a "super app," offering a wider range of asset and market options

Seizing two major hot areas! Coinbase is set to launch "prediction markets" and "tokenized stocks" all at once

RBC Capital Maintains Buy Rating on JPMorgan

Gerard Cassidy from RBC Capital maintained a Buy rating on JPMorgan Chase with a $330 price target. The stock closed at $317.38. The analyst has a 20.2% average return and a 73.02% success rate. The Street consensus is a Moderate Buy with a $336.07 average price target. TD Cowen also maintained a Buy rating with a $370 target.

JPMorgan Chase (JPM) Receives a Rating Update from a Top Analyst

JP Morgan recommends buying U.S. 2-year Treasury bonds at a yield level of approximately 3.60%, expecting the yield to potentially drop below 3.40% in the first quarter, and even fall below 3.30%. The team suggests going long by 25% at market price, adding another 25% around 3.65%, with a stop-loss set at 3.72%

JP Morgan recommends buying 2-year U.S. Treasury bonds around 3.60%

JPMorgan Increases Voting Rights in PNE AG to 5.54%

JPMorgan Chase & Co. has increased its voting rights in PNE AG from 5.46% to 5.54%, marking a 0.08% rise. This information was originally published by PNE AG via EQS News on December 11, 2025.

JPMorgan Chase & Co. Increases Total Voting Rights in PNE AG to 5.54%

JPMorgan Chase & Co. has increased its voting rights in SSE Plc to 5.92%, crossing the previous threshold of 5.23%. This change was notified on December 2, 2025, following the crossing of the threshold on November 28, 2025. The holdings include both direct voting rights and financial instruments, with J.P. Morgan Securities plc as the shareholder. The announcement was made via RNS, the news service of the London Stock Exchange.

REG - SSE Plc JPMorgan Chase & Co - Holding(s) in Company

JPMorgan Chase & Co. has increased its voting rights in Covestro AG from 5.98% to 6.25%, marking a 0.27 percentage point rise. This change reflects an adjustment in JPMorgan's stake in Covestro AG, as reported by Public Technologies using AI-generated content. The original content was published by Covestro AG via EQS News on December 01, 2025.

JPMorgan Chase & Co. increases total voting rights in Covestro AG to 6.25%

JPMorgan Increases Stake in Innovent Biologics to 5.08%

According to the latest information from the Hong Kong Stock Exchange, on November 24th, Morgan Stanley increased its holdings in INNOVENT BIO by 1,635,942 shares, at a price of HKD 90.9102 per share, totaling approximately HKD 149 million. After the increase, the latest number of shares held is approximately 87,161,800, with a latest holding ratio of 5.08%

Morgan Stanley increased its holdings in INNOVENT BIO by approximately 1.6359 million shares at a price of about HKD 90.91 per share

According to the latest data from the Hong Kong Stock Exchange, on October 30, Morgan Stanley increased its holdings in INNOVENT BIO by 2,550,546 shares, at a price of HKD 80.6819 per share, for a total amount of approximately HKD 206 million. After the increase, the latest number of shares held is approximately 87,023,200, with a latest holding ratio of 5.07%

Morgan Stanley increased its holdings in INNOVENT BIO by approximately 2.5505 million shares at a price of about HKD 80.68 per share

According to the latest data from the Hong Kong Stock Exchange, on November 11, Morgan Stanley increased its holdings in INNOVENT BIO by 1,438,757 shares, at a price of HKD 84.7327 per share, totaling approximately HKD 122 million. After the increase, the latest number of shares held is approximately 86,841,100, with a latest holding ratio of 5.06%

Morgan Stanley increased its holdings in INNOVENT BIO by approximately 1.4388 million shares at a price of about HKD 84.73 per share

INNOVENT BIO once rose nearly 5%, and as of the time of publication, it is up 3.9%, trading at HKD 90.65, with a transaction volume of HKD 177 million. On the news front, on November 21, the results of the Hang Seng Index series quarterly review were released, and all changes will take effect from December 8, 2025. Among them, INNOVENT BIO will be included in the Hang Seng Index constituent stocks, increasing the number of constituent stocks from 88 to 89. It is worth mentioning that on November 20, INNOVENT BIO announced that the phase III clinical study (GLORY-2) of Masitide injection (glucagon [GCG] / glucagon-like peptide-1 [GLP-1] dual receptor agonist, research code: IBI362) conducted in the Chinese population with moderate to severe obesity has achieved its primary endpoint and all key secondary endpoints. INNOVENT BIO will soon submit a new drug application for Masitide 9mg for adult weight control to regulatory authorities

Understanding the Market | INNOVENT BIO once rose nearly 5% and will officially turn blue starting from December 8

Innovent Biologics has been included in the Hang Seng Index constituents, becoming the first Chinese pharmaceutical company to grow from Biotech to Biopharma and enter the blue-chip category. This marks the first time that China's innovative drug industry has been accepted by the mainstream international capital market as a core asset, promoting a shift in Innovent Biologics' valuation system from growth stocks to asset stocks, and the evaluation logic of the capital market is also undergoing a fundamental change

Innovent Bio has been included in the Hang Seng Index, signaling the entry of Chinese biotech into the era of mainstream assets

JPMorgan Seeks SEC Approval for Bitcoin Structured Note Product

JP Morgan has applied to the U.S. Securities and Exchange Commission to launch a structured note product linked to Bitcoin. This product allows investors to bet on Bitcoin prices through BlackRock iShares Bitcoin Trust ETF. If the Bitcoin ETF price reaches or exceeds a set price by December 21, 2026, JP Morgan will redeem the notes and pay at least $160. If the price is below the standard, the notes will be held until 2028, and investors can earn a return of 1.5 times the increase in Bitcoin. The product carries high risks; if the Bitcoin price drops by 40% or more, investors will lose most of their initial investment

JP Morgan applies to the U.S. SEC for a Bitcoin structured note product

JPMorgan Chase has launched structured notes linked to the BlackRock spot Bitcoin ETF (IBIT), designed to align with the Bitcoin halving cycle. If IBIT reaches the target price in 2026, the notes will be automatically redeemed, providing investors with a 16% return; if the target is not met, it will extend to 2028, and if the target price is exceeded, investors can receive more than 1.5 times the return. The product includes downside protection, ensuring that if IBIT's decline does not exceed 30% by 2028, the principal is protected; losses will be proportional if it exceeds 30%. JPMorgan Chase warns of extreme downside risks, with investors potentially losing over 40% of their principal

JPMorgan Chase launched structured notes linked to BlackRock's IBIT, aligning with the Bitcoin halving cycle

JP Morgan significantly increased its holdings in Bitcoin ETF, raising its shares to 5,284,190, with a total market value of approximately $343 million, an increase of 64%. The bank also holds options positions in IBIT, including $68 million in call options and $133 million in put options. Despite the volatility in Bitcoin prices, JP Morgan remains confident in its long-term prospects, reflecting a rebound in market demand for regulated investment instruments. Analysts point out that there is still a discount for Bitcoin relative to gold